Trends in the Utilization of, Spending on, and Prices for Outpatient Antifungal Agents in US Medicaid Programs: 1991-2009

Clinical Therapeutics

Volumn 34, Issue 10, 2012, Pages

  Desai, Vibha C A ^a   Cavanaugh, Teresa M ^a   Kelton, Christina M L ^b   Guo, Jeff J ^a   Heaton, Pamela C ^a  

^a UNIVERSITY OF CINCINNATI ACADEMIC HEALTH CENTER   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Antifungal agents; Antifungal drug utilization; Invasive fungal infections; Medicaid; Superficial fungal infections

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; BUTENAFINE; CASPOFUNGIN; CICLOPIROX; ECONAZOLE; FLUCONAZOLE; GRISEOFULVIN; ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; MICONAZOLE; NAFTIFINE; NYSTATIN; OXICONAZOLE; POSACONAZOLE; SERTACONAZOLE; SULCONAZOLE; TERBINAFINE; TERCONAZOLE; TIOCONAZOLE; VORICONAZOLE;

ARTICLE; DRUG COST; DRUG THERAPY; HOSPITAL UTILIZATION; MEDICAID; MEDICAL EDUCATION; MEDICARE; OUTPATIENT; PRESCRIPTION; REIMBURSEMENT; UNITED STATES;

EID: 84867345197     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.09.003     Document Type: Article

References (52)

1. Hobson R. The global epidemiology of invasive Candida infections-is the tide turning?. J Hosp Infect 2003, 55:159-168.
2. Garbino J., Kolarova L., Rohner P., et al. Secular trends of candidemia over 12 years in adult patients at a tertiary care hospital. Medicine 2002, 81:425-433.
3. Enoch D., Ludlam H., Brown N. Invasive fungal infections: a review of epidemiology and management options. J Med Microbiol 2006, 55:809-818.
4. Pfaller M.A., Pappas P.G., Wingard J.R. Invasive fungal pathogens: current epidemiological trends. Clin Infect Dis 2006, 43(Suppl 1):S3-S14.
5. Gallis H.A., Drew R.H., Pickard W.W. Amphotericin B: 30 years of clinical experience. Clin Infect Dis 1990, 12:308-329.
6. Maertens J. History of the development of azole derivatives. Clin Microbiol Infect 2004, 10:1-10.
7. Lister J. Amphotericin B lipid complex (Abelcet) in the treatment of invasive mycoses: the North American experience. Eur J Haematol 1996, 56(Suppl 57):18-23.
8. Herbrecht R., Denning D., Patterson T., et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002, 347:408-415.
9. Perfect J., Marr K., Walsh T., et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003, 36:1122-1131.
10. Denning D. Echinocandin antifungal drugs. Lancet 2003, 362:1142-1151.
11. Papon N., Noël T., Florent M., et al. Molecular mechanism of flucytosine resistance in Candida lusitaniae: Contribution of the FCY2, FCY1, and FUR1 genes to 5-fluorouraciland fluconazole cross-resistance. Antimicrob Agents Chemother 2007, 51:369-371.
12. Vermes A., Guchelaar H.-J., Dankert J. Flucytosine: A review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother 2000, 46:171-179.
13. Pharmacotherapy: A Pathophysiologic Approach. 7th ed 2008, 1954-1964. Superficial fungal infections, McGraw-Hill, New York, NY. J.T. Dipiro, R.L. Talbert, C.Y. Gary (Eds.).
14. Sobel J.D., Chaim W., Nagappan V., Leaman D. Treatment of vaginitis caused by Candida glabrata: use of topical boric acid and flucytosine. Am J Obstet Gynecol 2003, 189:1297-1300.
15. Roberts D., Taylor W., Boyle J. Guidelines for treatment of onychomycosis. Br J Dermatol 2003, 148:402-410.
16. Gupta A., Baran R., Summerbell R. Onychomycosis: strategies to improve efficacy and reduce recurrence. J Eur Acad Dermatol Venereol 2002, 16:579-586.
17. Baran R., Kaoukhov A. Topical antifungal drugs for the treatment of onychomycosis: an overview of current strategies for monotherapy and combination therapy. J Eur Acad Dermatol Venereol 2005, 19:21-29.
18. Gupta A.K., Tu L.Q. Therapies for onychomycosis: a review. Dermatol Clin 2006, 24:375-379.
19. Leigh J.E., Shetty K., Fidel P.L. Oral opportunistic infections in HIV-positive individuals: review and role of mucosal immunity. AIDS Patient Care STDs 2004, 18:443-456.
20. Fidel P. Candida-host interactions in HIV disease: relationships in oropharyngeal candidiasis. Adv Dental Res 2006, 19:80-84.
21. Darouiche R.O. Oropharyngeal and esophageal candidiasis in immunocompromised patients: treatment issues. Clin Infect Dis 1998, 26:259-274.
22. Leading International Fungal Education. Nystatin, Accessed June 25, 2012. http://www.life-worldwide.org/fungal-diseases/nystatin/.
23. Sheehan D.J., Hitchcock C.A., Sibley C.M. Current and emerging azole antifungal agents. Clin Mirobiol Rev 1999, 12:40-79.
24. Mayo Clinic. Ketoconazole (oral route) Accessed June 25, 2012. http://www.mayoclinic.com/health/drug-information/DR602563.
25. Wieczorkiewicz S.M., Jourjy J., Danziger L. An update on the pharmacoeconomics of antifungal pharmacotherapy. Curr Fungal Infect Rep 2009, 3:103-110.
26. Menzin J., Meyers J.L., Friedman M., et al. Mortality, length of hospitalization, and costs associated with invasive fungal infections in high-risk patients. Am J Health System Pharm 2009, 66:1711-1717.
27. Ashley E.D. Pharmacoeconomics of antifungal therapy: current considerations. Curr Opin Infect Dis 2011, 24(Suppl):S30-S40.
28. Centers for Medicare & Medicaid Services. State Drug Utilization Data Accessed June 25, 2012. http://medicaid.gov/Medicaid-CHIP-Program-Information/By-Topics/Benefits/Prescription-Drugs/Medicaid-Drug-Rebate-Program-Data.html.
29. Drug Facts and Comparisons. Facts & Comparisons [database online]. St. Louis, MO: Wolters Kluwer Health, Inc; March 2005.
30. Centers for Medicare & Medicaid Services. National Health Expenditures by Type of Service and Source of Funds, CY 1960-2009 Accessed June 25, 2012. https://www.cms.gov/NationalHealthExpendData/02_NationalHealthAccountsHistorical.asp#TopOfPage.
31. Consumer Price Index. All Urban Consumers (CPI-U). US City Average Bureau of Labor Statistics, Accessed June 25. ftp://ftp.bls.gov/pub/special.requests/cpi/cpiai.txt.
32. Jing Y., Kelton C.M.L., Guo J.J., et al. Price, utilization, and spending for antipsychotic medications in the Medicaid program. Drug Benefit Trends 2007, 19:27-41.
33. Chiu S.-F., Kelton C.M.L., Guo J.J., et al. Utilization, spending, and price trends for long-acting beta agonists and inhaled corticosteroids in the U.S. Medicaid program from 1991 to 2010. Am Health Drug Benefits 2011, 4:140-149.
34. Chen Y., Kelton C.M.L., Jing Y., et al. Utilization, price, and spending trends for antidepressants in the US Medicaid program. Res Social Administrative Pharm 2008, 4:244-257.
35. Jing Y., Klein P., Kelton C.M.L., Li X., Guo J.J. Utilization and spending trends for antiretroviral medications in the U.S. Medicaid program from 1991 to 2005 Accessed June 25, 2012. http://www.aidsrestherapy.com/content/4/1/22.
36. Centers for Medicare & Medicaid Services. Data Compendium, 2010 Accessed June 25, 2012. http://www.cms.gov/DataCompendium/14_2010_Data_Compendium.asp#TopOfPage.
37. Kauffman C.A., Yoshikawa T.T. Fungal infections in older adults. Clin Infect Dis 2001, 33:550-555.
38. Azie N., Neofytos D., Pfaller M., et al. The PATH (Prospective Antifungal Therapy) Alliance registry and invasive fungal infections: update 2012. Diagn Microbiol Infect Dis 2012, 73:293-300.
39. Richardson M., Lass-Flörl C. Changing epidemiology of systemic fungal infections. Clin Microbiol Infect 2008, 14:5-24.
40. Saad A.H., DePestel D.D., Carver P.L. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy 2006, 26:1730-1744.
41. Eliopoulos G.M., Perea S., Patterson T.F. Antifungal resistance in pathogenic fungi. Clin Infect Dis 2002, 35:1073-1080.
42. Wong-Beringer A., Jacobs R.A., Guglielmo B.J. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis 1998, 27:603-618.
43. Wingard J.R., White M.H., Anaissie E., et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin Infect Dis 2000, 31:1155-1163.
44. Walsh T.J., Pappas P., Winston D.J., et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002, 346:225-234.
45. Greenberg R., Mullane K., Van Burik J.A.H., et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006, 50:126-133.
46. Wiederhold N.P., Lewis J.S. The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety. Expert Opin Pharmacother 2007, 8:1155-1166.
47. Wisconsin Medicaid and Badger Care, Department of Health and Family Services. Pharmacy covered services and reimbursement Accessed June 25, 2012. https://www.forwardhealth.wi.gov/kw/pdf/pharmacy_covered.pdf.
48. Iorizzo M., Piraccini B.M., Rech G., Tosti A. Treatment of onychomycosis with oral antifungal agents. Exp Opin Drug Deliv 2005, 2:435-440.
49. Lyman C., Walsh T. Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications. Drugs 1992, 44:9-35.
50. Schweitzer S.O. Pharmaceutical Economics Policy, ed 2 2007, Oxford University Press, New York, NY.
51. Dusing M.L., Guo J.J., Kelton C.M.L., Pasquale M.K. Competition and price discounts for a hospital buyer in the anti-infective pharmaceutical market. J Pharmaceutical Finance Economics Policy 2005, 14:59-85.
52. CMS Chronic Condition Data Warehouse (CCW) MAX Data. Medicaid enrollee counts for 1999 through 2007, Accessed June 25, 2012. http://www.ccwdata.org/cs/groups/public/documents/document/tablea2.pdf.